Clinical Perspectives

Fluorescent Imaging Technology Approved for Ovarian Cancer Surgery

December 06, 2021

Ovarian Near Infrared Illumination Credit: On Target Laboratories

The U.S. Food and Drug Administration (FDA) recently approved CYTALUX for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions.

Ovarian cancer is the number one cause of gynecologic cancer death in the United States. For women with ovarian cancer, treatment often consists of a combination of cytoreductive surgery and chemotherapy. With the approval usage of CYTALUX, surgeons would be able to administer the fluorescent imaging technology using the standard IV before surgery. CYTALUX agent binds to folate receptors that are overexposed in most epithelial ovarian cancer cases and light up intraoperatively under near-infrared light. This helps surgeons to identify malignant lesions that were not preplanned or detected by palpation and normal white light alone.

"The multidisciplinary experts at Moffitt Cancer Center were instrumental in the development of this technology as active investigators in the Phase 2 and randomized Phase 3 studies.  Our tissue core lab served as their central lab for study. There is a learning curve to the technology, but since we helped establish it over the last few years, we are looking forward to being one of the first to offer this to patients when it is commercially available.  The FDA approval of CYTALUX is a significant milestone that will advance the way we detect cancer. We know that survival is better with the more cancer that is removed. We helped show that this technology can help us find more cancer and is truly a game-changer,” said Gynecologic Program Chair Robert Wenham, MD

Robert Wenham, MD
Robert Wenham, MD, Chair, Gynecologic Oncology Program

The Department of Gynecologic Oncology at Moffitt Cancer Center is known for providing world-class, individualized treatment, as well as some of the highest survival rates and an improved quality of life. We offer the latest options in diagnostic imaging, laboratory testing and genetic screening, as well as innovations in surgery such as the development of the newly approved CYTALUX, chemotherapy, radiation therapy and hormone therapy. 

Our robust clinical trials program, in which some of our experts are leading investigators, provides patients with unique opportunities to benefit from promising new treatments before those options are made widely available in other settings.

If you’d like to refer a patient to Moffitt Cancer Center, complete our online form or contact a physician liaison for assistance. As part of our efforts to shorten referral times as much as possible, online referrals are typically responded to within 24 - 48 hours.